Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers

Fig. 5

Validation of NNT-AS1 expression in various cancers in TCGA cohort. a The expression levels of NNT-AS1 in SARC, STAD, LIHC, CHOL, and BRCA. b The expression levels of NNT-AS1 in LUAD, LUSC, COAD, READ, BLCA, and CESC. c Association between NNT-AS1 expression and clinical stage of cancers including SARC, STAD, LIHC, CHOL, COAD, BRCA, LUAD, LUSC, COAD, READ, BLCA, and CESC in TCGA cohort. d OS plot of NNT-AS1 in TCGA cohort (n = 4127). e DFS plot of NNT-AS1 in TCGA cohort (n = 4127). BLCA (bladder urothelial carcinoma); BRCA (breast invasive carcinoma); CESC (cervical squamous cell carcinoma and endocervical adenocarcinoma); CHOL (cholangiocarcinoma); COAD (colon adenocarcinoma); DFS: disease-free survival; LIHC (liver hepatocellular carcinoma); LUAD (lung adenocarcinoma); LUSC (lung squamous cell carcinoma); NNT-AS1: nicotinamide nucleotide transhydrogenase antisense RNA 1; OS: overall survival; READ (rectum adenocarcinoma); SARC (sarcoma); STAD (stomach adenocarcinoma); TCGA: the Cancer Genome Atlas

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us